Genentech and Biogen pen royalty deal for blood cancer drug with big potential

Biogen’s collaboration with Genentech could pay off again in the form of US royalties for the potential blood cancer drug glofitamab, a CD20xCD3 bispecific.

Biogen will receive tiered royalties on potential net sales of glofitamab within the US and will have no payment obligations — if the drug gets approved....

Click to view original post